Senti Biosciences (SNTI) Stock Price, News & Analysis

Company Overview

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release. These platforms support a diverse pipeline of preclinical cell therapy programs targeting solid tumors, hematologic malignancies and autoimmune disorders.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Senti Biosciences completed its initial public offering in June 2021 and is listed on the Nasdaq exchange. The company collaborates with academic and industry partners to advance its research and expand its proprietary platform capabilities.

Senti is led by a management team combining expertise in synthetic biology, immunology and biotechnology development. The leadership team includes seasoned industry executives and academic scientists committed to translating circuit-based cell therapies into clinical applications worldwide.

Key Stats

• Today's Range: $1.38 to $1.42
• 50-Day Range: $1.30 to $2.35
• 52-Week Range: $1.26 to $16.94
• Volume: 20,775 shs
• Average Volume: 169,231 shs
• Market Capitalization: $36.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Buy

Senti Biosciences Stock Analysis - MarketRank™

Senti Biosciences scored higher than 68% of companies evaluated by MarketBeat, and ranked 350th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Senti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Senti Biosciences has a consensus price target of $8.50, representing about 507.1% upside from its current price of $1.40.

Amount of Analyst Coverage

Senti Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Senti Biosciences are expected to grow in the coming year, from ($14.54) to ($1.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Senti Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Senti Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Senti Biosciences has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.02% of the float of Senti Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Senti Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Senti Biosciences has recently decreased by 21.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Senti Biosciences does not currently pay a dividend.

Dividend Growth

Senti Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.02% of the float of Senti Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Senti Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Senti Biosciences has recently decreased by 21.68%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.45

News Sentiment

Senti Biosciences has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Senti Biosciences this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for SNTI on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Senti Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.12% of the stock of Senti Biosciences is held by insiders.

Percentage Held by Institutions

Only 25.73% of the stock of Senti Biosciences is held by institutions.

SNTI Stock Analysis - Frequently Asked Questions

How have SNTI shares performed this year?

Senti Biosciences' stock was trading at $3.51 at the beginning of 2025. Since then, SNTI shares have decreased by 60.1% and is now trading at $1.40.

How were Senti Biosciences' earnings last quarter?

Senti Biosciences, Inc. (NASDAQ:SNTI) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.02. The business earned $0.50 million during the quarter, compared to the consensus estimate of $1.30 million.

When did Senti Biosciences' stock split?

Shares of Senti Biosciences reverse split before market open on Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Senti Biosciences' major shareholders?

Senti Biosciences' top institutional shareholders include Armistice Capital LLC (3.41%) and Geode Capital Management LLC (0.56%).
View institutional ownership trends.

How do I buy shares of Senti Biosciences?

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Senti Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/17/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNTI
• CIK: 1854270
• Web: www.sentibio.com
• Phone: 650-239-2030
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Senti Biosciences: $8.50
• High Price Target: $12.00
• Low Price Target: $5.00
• Potential Upside/Downside: +515.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -223.98%
• Return on Assets: -76.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.26
• Quick Ratio: 3.26

Sales & Book Value

• Annual Sales: $2.56 million
• Price / Sales: 14.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.31 per share
• Price / Book: 0.26

Miscellaneous

• Outstanding Shares: 26,160,000
• Free Float: 25,344,000
• Market Cap: $36.13 million
• Optionable: Not Optionable
• Beta: 2.06